Cargando…

Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches

Introduction: Renal cell carcinomas (RCC) have been treated with immunotherapy for decades; the use of immune checkpoint inhibitors represents the most recent advance. In this review, we compare these new RCC immunotherapies, with a focus on achieving durable complete responses (CR). Review: Sorafen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kathuria-Prakash, Nikhita, Drolen, Claire, Hannigan, Christopher A., Drakaki, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781308/
https://www.ncbi.nlm.nih.gov/pubmed/35054417
http://dx.doi.org/10.3390/life12010024
_version_ 1784638060218023936
author Kathuria-Prakash, Nikhita
Drolen, Claire
Hannigan, Christopher A.
Drakaki, Alexandra
author_facet Kathuria-Prakash, Nikhita
Drolen, Claire
Hannigan, Christopher A.
Drakaki, Alexandra
author_sort Kathuria-Prakash, Nikhita
collection PubMed
description Introduction: Renal cell carcinomas (RCC) have been treated with immunotherapy for decades; the use of immune checkpoint inhibitors represents the most recent advance. In this review, we compare these new RCC immunotherapies, with a focus on achieving durable complete responses (CR). Review: Sorafenib and sunitinib were the first Food and Drug Administration (FDA)-approved targeted agents for RCC, with sunitinib eventually becoming the standard-of-care agent against which novel therapies are compared. In the last five years, many combination therapies based on the use of immune checkpoint inhibitors (ICIs) and receptor tyrosine kinase inhibitors (TKIs), including ipilimumab/nivolumab, nivolumab/cabozantinib, avelumab/axitinib, pembrolizumab/axitinib, and pembrolizumab/lenvatinib, have demonstrated superior overall survival (OS) and progression-free survival (PFS) compared to sunitinib. Ongoing clinical trials of hypoxia-induced factor-2 alpha (HIF-2a) inhibitors, chimeric antigen receptor T cell (CAR-T) therapy targeting CD70, and other new combination therapies have also shown promise and are currently under investigation. Conclusions: Many new combination therapies are approved for RCC treatment, and CR rates suggest that, in the era of immunotherapy, it may be possible to achieve durable responses and survival benefit in patients with metastatic RCC.
format Online
Article
Text
id pubmed-8781308
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87813082022-01-22 Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches Kathuria-Prakash, Nikhita Drolen, Claire Hannigan, Christopher A. Drakaki, Alexandra Life (Basel) Review Introduction: Renal cell carcinomas (RCC) have been treated with immunotherapy for decades; the use of immune checkpoint inhibitors represents the most recent advance. In this review, we compare these new RCC immunotherapies, with a focus on achieving durable complete responses (CR). Review: Sorafenib and sunitinib were the first Food and Drug Administration (FDA)-approved targeted agents for RCC, with sunitinib eventually becoming the standard-of-care agent against which novel therapies are compared. In the last five years, many combination therapies based on the use of immune checkpoint inhibitors (ICIs) and receptor tyrosine kinase inhibitors (TKIs), including ipilimumab/nivolumab, nivolumab/cabozantinib, avelumab/axitinib, pembrolizumab/axitinib, and pembrolizumab/lenvatinib, have demonstrated superior overall survival (OS) and progression-free survival (PFS) compared to sunitinib. Ongoing clinical trials of hypoxia-induced factor-2 alpha (HIF-2a) inhibitors, chimeric antigen receptor T cell (CAR-T) therapy targeting CD70, and other new combination therapies have also shown promise and are currently under investigation. Conclusions: Many new combination therapies are approved for RCC treatment, and CR rates suggest that, in the era of immunotherapy, it may be possible to achieve durable responses and survival benefit in patients with metastatic RCC. MDPI 2021-12-24 /pmc/articles/PMC8781308/ /pubmed/35054417 http://dx.doi.org/10.3390/life12010024 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kathuria-Prakash, Nikhita
Drolen, Claire
Hannigan, Christopher A.
Drakaki, Alexandra
Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches
title Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches
title_full Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches
title_fullStr Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches
title_full_unstemmed Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches
title_short Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches
title_sort immunotherapy and metastatic renal cell carcinoma: a review of new treatment approaches
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781308/
https://www.ncbi.nlm.nih.gov/pubmed/35054417
http://dx.doi.org/10.3390/life12010024
work_keys_str_mv AT kathuriaprakashnikhita immunotherapyandmetastaticrenalcellcarcinomaareviewofnewtreatmentapproaches
AT drolenclaire immunotherapyandmetastaticrenalcellcarcinomaareviewofnewtreatmentapproaches
AT hanniganchristophera immunotherapyandmetastaticrenalcellcarcinomaareviewofnewtreatmentapproaches
AT drakakialexandra immunotherapyandmetastaticrenalcellcarcinomaareviewofnewtreatmentapproaches